Article

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Author(s):

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Related Videos
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Greg A. Sachs, MD I Credit: Regenstrief Institute
3 experts are featured in this series.
Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire
© 2025 MJH Life Sciences

All rights reserved.